Press release
Coccidioidomycosis Pipeline Drugs Report 2025: Innovative Infectious Diseases Approaches and Pharma Opportunities | DelveInsight
Curious about the latest updates in the Coccidioidomycosis Pipeline? Click here to explore the therapies and trials making headlines @ Coccidioidomycosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/coccidioidomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Coccidioidomycosis Pipeline Report
* DelveInsight's Coccidioidomycosis Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Coccidioidomycosis treatment.
* The leading Coccidioidomycosis Companies such as SCYNEXIS, Mycovia Pharmaceuticals, Amplyx Pharmaceuticals, F2G and others.
* Promising Coccidioidomycosis Therapies such as Posaconazole, Fluconazole, Olorofim, Ibrexafungerp and others.
Want to know which companies are leading innovation in Coccidioidomycosis? Dive into the full pipeline insights @ Coccidioidomycosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/coccidioidomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Coccidioidomycosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Coccidioidomycosis Pipeline Report also highlights the unmet needs with respect to the Coccidioidomycosis.
Coccidioidomycosis Overview
Coccidioidomycosis is caused by Coccidioides immitis, a soil fungus native to the San Joaquin Valley of California, and by C posadasii, which is endemic to certain arid-to-semiarid areas of the southwestern United States, northern portions of Mexico, and scattered areas in Central America and South America. Although genetically distinct, the 2 species are morphologically identical. Coccidioidomycosis is typically transmitted by inhalation of airborne spores of C immitis or C posadasii. Infection occurs in endemic areas and is most commonly acquired in the summer or the late fall during outdoor activities.
Coccidioidomycosis Emerging Drugs Profile
* Ibrexafungerp: SCYNEXIS
Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).
* VT-1598: Mycovia Pharmaceuticals
Mycovia is currently evaluating VT-1598, an oral antifungal, in Phase 1 clinical trials, for the treatment of serious fungal pathogens that pose a growing global threat due to underlying multidrug resistance. VT-1598 has QIDP designation, Fast Track status, and orphan designation for Valley fever (coccidioides); cryptococcal meningitis is eligible for FDA's priority review voucher program.
If you're tracking ongoing Coccidioidomycosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Coccidioidomycosis Treatment Drugs [https://www.delveinsight.com/sample-request/coccidioidomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Coccidioidomycosis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Coccidioidomycosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Coccidioidomycosis Treatment.
* Coccidioidomycosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Coccidioidomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Coccidioidomycosis market.
Coccidioidomycosis Companies
SCYNEXIS, Mycovia Pharmaceuticals, Amplyx Pharmaceuticals, F2G and others.
Coccidioidomycosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Coccidioidomycosis Products have been categorized under various Molecule types such as,
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
From emerging drug candidates to competitive intelligence, the Coccidioidomycosis Pipeline Report covers it all - check it out now @ Coccidioidomycosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/coccidioidomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Coccidioidomycosis Pipeline Report
* Coverage- Global
* Coccidioidomycosis Companies- SCYNEXIS, Mycovia Pharmaceuticals, Amplyx Pharmaceuticals, F2G and others.
* Promising Coccidioidomycosis Therapies- Posaconazole, Fluconazole, Olorofim, Ibrexafungerp and others.
* Coccidioidomycosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Coccidioidomycosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Coccidioidomycosis Treatment landscape in this detailed analysis @ Coccidioidomycosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/coccidioidomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Coccidioidomycosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Coccidioidomycosis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Ibrexafungerp: SCYNEXIS
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* VT-1598: Mycovia Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Coccidioidomycosis Key Companies
* Coccidioidomycosis Key Products
* Coccidioidomycosis- Unmet Needs
* Coccidioidomycosis- Market Drivers and Barriers
* Coccidioidomycosis- Future Perspectives and Conclusion
* Coccidioidomycosis Analyst Views
* Coccidioidomycosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=coccidioidomycosis-pipeline-drugs-report-2025-innovative-infectious-diseases-approaches-and-pharma-opportunities-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/coccidioidomycosis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Coccidioidomycosis Pipeline Drugs Report 2025: Innovative Infectious Diseases Approaches and Pharma Opportunities | DelveInsight here
News-ID: 4212653 • Views: …
More Releases from ABNewswire
Jesus Empire Launches 4G/5G Mobile Proxies to Empower Safe, U.S.-Sourced Social …
Real rotating 4G/5G LTE IPs (U.S. only) for safer multi-account management, geo-targeting, and automated engagement
Jesus Empire today announced the launch of Jesus Empire 4G/5G Mobile Proxies [https://jesusempire.com/jesus-empire-5g-mobile-proxies/], a next-generation proxy service providing real rotating U.S.-sourced 4G and 5G LTE IP addresses for creators, marketers, and automation agencies. By delivering genuine mobile IPs from U.S. carriers, Jesus Empire's proxies help clients scale social media campaigns with enhanced account safety, reduced ban…
Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill …
Antibiotic resistance has become one of medicine's most urgent challenges. The CDC estimates that resistant infections cause ~35,000 deaths each year in the U.S. and more than 1 million globally - a number projected to rise sharply over the next 25 years. Traditional drug development is struggling to keep pace, forcing healthcare systems to look beyond antibiotics altogether.
That search has reignited interest in a century-old idea that suddenly looks like…
Dermis Advanced Skin Care Introduces Cutting-Edge HydraFacial Technology to Otta …
Dermis Advanced Skin Care introduces cutting-edge HydraFacial technology to Ottawa's medical skin care clinic landscape. The non-invasive treatment delivers deep cleansing, exfoliation, and hydration for instantly radiant skin. Suitable for all skin types, HydraFacial reflects Dermis' commitment to innovation and excellence in advanced aesthetic care.
Ottawa, ON - October 27, 2025 - The growing demand for non-invasive facial rejuvenation continues to shape Ottawa's medical aesthetics scene, as Dermis Advanced Skin Care,…
Veltry Law, PC Gets Traffic Citation Points Dismissed and Massively Reduces Fine …
Islip, NY - Oct 27, 2025 - Veltry Law, PC, 309 Main St #1, Islip, NY 11751 [https://wwfvlaw.com/] (631) 234-5678, a respected Long Island, New York law firm, is proud to announce they are continuing the practice of reducing fines and erasing suspended license citations for traffic ticket offenses and aggravated unlicensed operation (AUO) in Suffolk and Nassau counties of Long Island, New York at their new location. 700+ 5-Star…
More Releases for Coccidioidomycosis
Coccidioidomycosis (Valley Fever) market is expected to reach USD 1.2 billion by …
Coccidioidomycosis, commonly known as Valley Fever, is a fungal infection caused by Coccidioides immitis and Coccidioides posadasii. It is endemic to arid regions of the Americas, particularly the southwestern United States, Mexico, and parts of Central and South America.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71957
The disease manifests with flu-like symptoms, pneumonia, and in severe cases, chronic pulmonary infection or disseminated disease affecting bones, skin, or the central…
Coccidioidomycosis Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Coccidioidomycosis pipeline constitutes 3+ key companies continuously working towards developing 3+ Coccidioidomycosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Coccidioidomycosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Coccidioidomycosis Market.
The Coccidioidomycosis Pipeline report embraces in-depth…
Coccidioidomycosis Drug Market - Industry Trends and Forecast to 2033
The global Coccidioidomycosis Drug Market was valued at approximately USD 432 million in 2023 and is projected to reach around USD 779 million by 2033, growing at a CAGR of 6.1% from 2024 to 2033.
Coccidioidomycosis Drug Market Overview
The Coccidioidomycosis Drug Market is witnessing gradual growth due to rising awareness and increasing diagnosis of coccidioidomycosis, commonly known as Valley Fever. The disease is prevalent in specific geographic regions, particularly in the…
Coccidioidomycosis Market Share, Epidemiology, Industry Trends and Forecast 2024 …
Market Overview:
The coccidioidomycosis market reached a value of US$ 132.9 Million in 2023 and expected to reach US$ 1,270.2 Million by 2034, exhibiting a growth rate (CAGR) of 7.3% during 2024-2034.
The report offers a comprehensive analysis of the coccidioidomycosis market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the…
Coccidioidomycosis Drug Market Growth, Analysis Report, Share, Trends and Overvi …
The most successful brands rely on data to inform, and gauge their strategy and decision making, from their marketing segmentation to the product features they develop. This Coccidioidomycosis Drug Market study report also aims at providing important market growth updates to enable business owners devise crucial marketing strategies. Business related decision making completely relies on market data and here comes the role of Coccidioidomycosis Drug Market research report. Making insight-driven…
Coccidioidomycosis Drug Market Trends 2022 | Segmentation, Outlook, Industry Rep …
The global coccidioidomycosis drug market is expected to grow at a significant CAGR during the forecast period (2022-2028). The fungal infection causes coccidioidomycosis, popularly known as valley fever. The fungus that causes coccidioidomycosis is called coccidioides, and it lives in soil in Mexico, the southern US, Central America, and South America. Valley fever is spread by inhaling fungus spores that are present in the air. Valley fever is characterized by…
